Latest 26 News in the Life Sciences Industry
GlobeNewswire
Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine
16 Apr 2026
GlobeNewswire
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
15 Apr 2026
GlobeNewswire
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
14 Apr 2026
GlobeNewswire
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
13 Apr 2026
GlobeNewswire
Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
09 Apr 2026
GlobeNewswire
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
09 Apr 2026
GlobeNewswire
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
09 Apr 2026
GlobeNewswire
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
27 Mar 2026
GlobeNewswire
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
25 Mar 2026
GlobeNewswire
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
25 Mar 2026
PR Newswire Association LLC.
Wegovy®▼(semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥27 kg/m2)[1]
01 Apr 2026
PR Newswire Association LLC.
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
28 Jan 2026
PR Newswire Association LLC.
Brazil Achieves a Historic Milestone: Blau Farmacêutica Fully Develops One of the World's Most Advanced Biosimilars Immunotherapies
23 Jan 2026
PR Newswire Association LLC.
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer
05 Dec 2025
PR Newswire Association LLC.
Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease
24 Nov 2025
PR Newswire Association LLC.
Green Science Alliance Made Quantum Dot from Plastic Wastes
11 Nov 2025
PR Newswire Association LLC.
Green Science Alliance Made Quantum Dot from Municipal Solid Waste
11 Nov 2025
PR Newswire Association LLC.
Green Science Alliance Developed Quantum Dot Type Pesticides from Organic Waste (Waste Tea Leaves, Waste Coffee Beans, Waste Woods)
07 Nov 2025
Upcoming Events All Events
- April 2026
- Seattle: Life Science Innovation Northwest 2026
- Leipzig: German Biotech Days
- Shanghai: ChinaBio® Partnering Forum